Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyModa Health denosumab Prior Auth & Coverage | Open…
    Ask Trek AI about this page
    CurrentModa HealthPolicy M-0098

    Denosumab (Prolia, Xgeva, biosimilars) — medical necessity and prior authorization criteria

    Customize your policy alerts

    Sign up for Moda Health Policy M-0098 alerts

    Get alerted when Policy M-0098 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity, dosing limits, authorization periods, and coverage criteria for denosumab products for members in scope of Moda Health. Applies to providers requesting prior authorization for denosumab formulations listed in the policy.

    Policy Summary
    PayerModa Health
    PolicyDenosumab (M-0098) — coverage criteria for Prolia, Xgeva, and biosimilars
    Policy CodePolicy M-0098
    Change TypeNo material changes
    Effective DateMay 5, 2026
    Last ReviewMay 5, 2026
    Next Review DateMay 5, 2026
    Key ActionObtain prior authorization (initial PA valid 12 months; renew every 12 months) and document calcium/vitamin D supplementation plus indication-supporting diagnostics or prior bisphosphonate trial when required.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 moinitial prior authorization validity
    60 units/6 moosteoporosis dosing limit
    120 units/q4woncology/GCT dosing limit
    60 mg q6m

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Prolia dose
    120 mg q4wXgeva dose
    Appendix ANQTL checklist

    Coverage Criteria for Denosumab Products

    Initial Approval — Osteoporosis

    Covered when ALL of the following are met for Prolia and listed osteoporosis denosumab products:

    Age: Member is at least 18 years of age
    Supplementation and lab status: Member must be supplementing with 1,000 mg calcium and at least 400 IU vitamin D daily; member must not have hypocalcemia
    CKD monitoring: Members with eGFR <30 mL/min/1.73 m2 (including dialysis-dependent) will be monitored for CKD-MBD with intact PTH (iPTH), serum calcium, 25(OH) vitamin D, and 1,25(OH)2 vitamin D prior to decisions regarding denosumab
    Pregnancy check: Pregnancy is ruled out prior to administration in biologic females of child-bearing potential
    Concomitant therapy exclusion: Will not be used in combination with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/related peptides
    Osteoporosis specifics: For osteoporosis: biological female must be post-menopausal; member must be at high risk for fracture; member must have documented osteoporosis by DXA T-score ≤ -2.5 OR history of hip or spine fragility fracture OR T-score between -1.0 and -2.5 plus qualifying fracture history or FRAX thresholds

    High risk examples and diagnostic thresholds per DXA, fragility fracture history, or FRAX are required

    Prior therapy requirement for osteoporosis: Member has documented treatment failure or ineffective response to a minimum 12-month trial of bisphosphonates (oral or IV) OR has documented contraindication or intolerance to BOTH oral and IV bisphosphonates

    Ineffective response defined as decrease in T-score vs baseline or new fracture while on bisphosphonate therapy

    Initial Approval — Glucocorticoid-Induced Osteoporosis

    Covered when ALL of the following are met for glucocorticoid-induced osteoporosis:

    Glucocorticoid exposure: Member will be initiating or is continuing systemic glucocorticoid therapy at a daily dosage equivalent to ≥2.5 mg prednisone and is expected to remain on therapy for at least 3 months≥2.5 mg prednisone daily, expected ≥3 months
    Increased fracture risk: Member must be at an increased risk for fracture

    Increased risk examples include prior fracture, high-dose glucocorticoids, FRAX thresholds, or T-score ≤ -2.5

    Prior therapy requirement for GIOP: Documented treatment failure after a minimum 12-month trial on bisphosphonates OR documented contraindication/intolerance to BOTH oral and IV bisphosphonates

    Initial Approval — Cancer therapy–related osteoporosis

    Covered when ALL of the following are met for osteoporosis related to prostate or breast cancer:

    Prostate cancer: Member must be receiving androgen deprivation therapy and be at high risk for fracture
    Breast cancer: Member must be receiving adjuvant aromatase inhibitor therapy for breast cancer

    Indication-specific initial coverage criteria

    Covered when ALL applicable universal criteria and the indication-specific criteria below are met

    Universal requirements: Member will receive calcium and vitamin D as necessary; member must not have hypocalcemia; denosumab will not be used in combination with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/related peptides.

    Universal Criteria per policy (supplementation, absence of hypocalcemia, pregnancy check, contraindicated combinations)

    Prevention of skeletal-related events (MM/bone mets): Member ≥ 18 years AND (trial of zoledronic acid ≥ 3 months with inadequate response, contraindication, or intolerance) OR member has metastatic breast cancer, metastatic castration-resistant prostate cancer, or metastatic lung cancer (SCLC or NSCLC)

    Prior bisphosphonate trial generally required unless exception

    Giant Cell Tumor of Bone (GCT): Member is adult or ≥12 years and skeletally mature AND disease is unresectable or surgery would cause severe morbidity OR disease is localized, recurrent, or metastatic; denosumab may be used as single agent or with embolization and/or radiation

    GCT entries flagged to FDA/compendia where noted

    Renewal criteria

    Renewal criteria — prior authorization validity can be renewed when ALL of the following are met

    Continued eligibility: Member continues to meet universal and indication-specific criteria (excluding prerequisite therapy) including concomitant therapy requirements and performance status

    Renewal references continued meeting of sections III and universal criteria

    Toxicity: Absence of unacceptable toxicity from the drug (examples: severe symptomatic hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, severe dermatologic reactions, severe infection, severe hypersensitivity/anaphylaxis, severe musculoskeletal pain)

    Examples of unacceptable toxicity provided in policy

    Beneficial disease response: Demonstrated benefit such as absence of fractures or increase in bone mineral density; or indication-specific responses (absence/delay in skeletal-related events for MM/bone metastases; stabilization or decrease in GCT tumor size; corrected serum calcium ≤11.5 mg/dL for hypercalcemia; improvement/resolution of bone pain for systemic mastocytosis)

    Examples listed per indication

    Medical necessity and administrative materials (partial)

    Policy includes medical necessity criteria and appendices (coding, NDCs, references, NQTL checklist) but specific stepwise criteria are not present in this segment.

    policy content: Includes HCPCS/Q/J codes, NDC lists, references, NQTL checklist, and covered diagnosis codes

    Appendices list product-specific HCPCS/Q/J codes, NDCs, and an NQTL factor checklist used to inform prior authorization

    Prolia-related coverage

    Covered for Prolia and related products when diagnosis matches listed ICD-10 codes

    Prolia group diagnoses: Any single ICD-10 code or code range listed under the Prolia product grouping (osteoporosis, pathological fracture codes, adverse effects of glucocorticoids, history codes) is acceptable to support coveragepresence of listed ICD-10 code

    See Appendix 1 (chunks 54-55) for exact Prolia-group ICD-10 codes

    Xgeva-related coverage

    Covered for Xgeva and related products when diagnosis matches listed ICD-10 codes

    Xgeva/oncology group diagnoses: Any single ICD-10 code or code range listed under the Xgeva product grouping (malignancy-related and bone tumor diagnoses, systemic mast cell disease, hypercalcemia) is acceptable to support coveragepresence of listed ICD-10 code

    See Appendix 1 (chunks 56-58) for exact Xgeva-group ICD-10 codes

    Medicare applicability

    Medicare-covered claims

    Medicare NCD/LCD compliance: Where the member is Medicare Part B, coverage is subject to applicable NCDs, LCDs, and Articles and MAC jurisdiction rules; providers must follow those documents for Medicare claimsN/A

    Appendix 2 directs providers to consult CMS coverage database and lists MAC jurisdictions

    Use in combination with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/related peptides is excluded.

    Use in combination with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/related peptides is not allowed.

    Note: J3590 (Unclassified biologics) is marked for discontinuation of use on 07/01/2026. Do not bill denosumab products under J3590 after that date.

    Appendix material is intended for non‑Medicare coverage determinations. For Medicare Part B claims, coverage and payment are governed by CMS manuals and any applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs); providers must follow those documents when billing Medicare.

    Caution: Denosumab administration is contraindicated when a member has hypocalcemia. Members must not have hypocalcemia prior to treatment, and clinicians should correct hypocalcemia before dosing.

    Operational note: If hypocalcemia is present or if a member meets contraindications to bisphosphonates (for example, documented pre‑existing hypocalcemia or renal insufficiency with creatinine clearance < 30–35 mL/min), denosumab treatment would be inappropriate and may result in denial unless the contraindication is specifically documented and aligns with indication‑specific exception criteria.

    Prior authorization is required for denosumab products and is applied based on the plan’s utilization management (NQTL) assessment; specific biosimilar Q‑codes and certain J‑codes are listed in the policy and inform PA decisions.

    Providers must verify Medicare applicability before submitting claims: Medicare Part B coverage is subject to CMS manuals and any applicable NCDs/LCDs/Articles and Local Coverage Articles; failure to follow applicable Medicare coverage documents may affect payment and prior authorization decisions.

    Prior authorization may be invalid and claims at risk for denial if the member has hypocalcemia, is not documented as receiving recommended calcium and vitamin D supplementation (standard: 1,000 mg calcium and at least 400 IU vitamin D daily per the Universal Criteria), or if denosumab is used in prohibited combinations with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/related peptides.

    When submitting PA or billing, include product‑specific documentation: appropriate HCPCS/Q/J code or NDC for the denosumab product administered. Note that J3590 is discontinued for use effective 07/01/2026, and Medicare claims must follow NCD/LCD guidance as noted in Appendix 2.

    Denial Risk

    Denial risk: hypocalcemia, missing supplementation, and prohibited combinations

    Prior authorization may be denied if the member has untreated hypocalcemia or is not receiving required calcium and vitamin D supplementation; denials also apply if denosumab is used concurrently with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/related peptides.

    • Member must not have hypocalcemia.
    • Member will receive calcium and vitamin D as necessary to treat or prevent hypocalcemia.
    • Denosumab will not be used in combination with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/related peptides.

    Billing, HCPCS, NDCs and Diagnosis Codes

    Dosing HCPCS unit guidanceHCPCS
    HCPCS (unspecified unit counts listed)Max units per dose and over time listed by product group (e.g., 60 billable units every 6 months for osteoporosis products; 120 billable units loading/maintenance schedules for oncology/GCT indications).
    Prolia & XgevaHCPCS
    J0897Injection, denosumab, 1 mg; 1 billable unit = 1 mg
    Jubbonti, Wyost; Osenvelt, Stoboclo, & Denosumab-bmwoHCPCS
    Q5136Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg; 1 billable unit = 1 mg
    Q5157Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg; 1 billable unit = 1 mg
    Bomyntra, Conexxence, & Denosumab-bnhtHCPCS
    Q5158Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg; 1 billable unit = 1 mg
    Denosumab-dssb, Ospomyv, & XbrykHCPCS
    Q5159Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg; 1 billable unit = 1 mg
    Aukelso, Bosaya, Bildyos, Bilprevda, Enoby, Xtrenbo, miscHCPCS
    Q5161Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg; 1 billable unit = 1 mg
    Q5162Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg; 1 billable unit = 1 mg
    J3590Unclassified biologics (Discontinue use on 07/01/2026)
    Q5167Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg; 1 billable unit = 1 mg (Effective 07/01/2026)
    HCPCS/Q/J Codes listedHCPCS
    Q5159Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg; 1 billable unit = 1 mg
    Q5161Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg; 1 billable unit = 1 mg
    Q5162Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg; 1 billable unit = 1 mg
    Q5167Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg; 1 billable unit = 1 mg (Effective 07/01/2026)
    Q5166Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg; 1 billable unit = 1 mg (Effective 07/01/2026)
    Q5171Injection, denosumab-mobz (boncresa), biosimilar, 1 mg; 1 billable unit = 1 mg (Effective 07/01/2026)
    Q5165Injection, denosumab-mobz (oziltus), biosimilar, 1 mg; 1 billable unit = 1 mg (Effective 07/01/2026)
    J3590Unclassified biologics (Discontinue use on 07/01/2026)
    NDCs listedNDC
    55513-0710-xxProlia 60 mg/1 mL single-dose prefilled syringe NDC
    61314-0240-xxJubbonti 60 mg/1 mL single-dose prefilled syringe NDC
    71202-0012-xxOspomyv 60 mg/1 mL single-dose prefilled syringe NDC
    71202-0013-xxDenosumab-dssb 60 mg/1 mL single-dose prefilled syringe NDC
    72606-0037-xxStoboclo 60 mg/1 mL single-dose prefilled syringe NDC
    72606-0058-xxDenosumab-bmwo 60 mg/1 mL single-dose prefilled syringe NDC
    65219-0668-xxConexxence 60 mg/1 mL single-dose prefilled syringe NDC
    65219-0680-xxDenosumab-bnht 60 mg/1 mL single-dose prefilled syringe NDC
    78206-0193-xxBildyos 60 mg/1 mL single-dose prefilled syringe NDC
    78206-0194-xxBildyos 60 mg/1 mL single-dose vial NDC
    1–10 of 28
    1/3
    Covered ICD-10 CodesICD-10Covered
    C50.011-C50.929Malignant neoplasms of breast
    C61Malignant neoplasm of prostate
    D05.10-D05.92Carcinoma in situ of breast (various laterality/specified codes listed)
    M80.00XA-Age-related osteoporosis with current pathological fracture (range indicated)
    M80.8B2A-M80.8B2SOsteoporosis with current pathological fracture
    M80.8B9A-M80.8B9SOsteoporosis with current pathological fracture (additional ranges)
    M81.0Age-related osteoporosis without current pathological fracture
    M81.6Localized osteoporosis [Lequesne]
    M81.8Other osteoporosis without current pathological fracture
    M85.80Other specified disorders of bone density and structure, unspecified site
    1–10 of 16
    1/2
    Prolia-related covered ICD-10 codesICD-10Covered
    C50.011-C50.929Malignant neoplasms of breast
    C61Malignant neoplasm of prostate
    D05.10Intraductal carcinoma in situ of unspecified breast
    D05.11Intraductal carcinoma in situ of right breast
    D05.12Intraductal carcinoma in situ of left breast
    D05.80Other specified type of carcinoma in situ of unspecified breast
    D05.81Other specified type of carcinoma in situ of right breast
    D05.82Other specified type of carcinoma in situ of left breast
    D05.91Unspecified type of carcinoma in situ of right breast
    D05.92Unspecified type of carcinoma in situ of left breast
    1–10 of 26
    1/3
    Xgeva/oncology-related covered ICD-10 codesICD-10Covered
    C00-C14Malignant neoplasms of lip, oral cavity and pharynx
    C15-C26Malignant neoplasms of digestive organs
    C30-C39Malignant neoplasms of respiratory and intrathoracic organs
    C40-C41Malignant neoplasms of bone and articular cartilage
    C43-C44Melanoma and other malignant neoplasms of skin
    C45-C49Malignant neoplasms of mesothelial and soft tissue
    C50.011-C50.929Malignant neoplasms of breast
    C51-C58Malignant neoplasms of female genital organs
    C60-C63Malignant neoplasms of male genital organs
    C64-C68Malignant neoplasms of urinary tract
    1–10 of 33
    1/4
    Medicare coverage guidancemixed
    Medicare Part BMedicare outpatient drug coverage governed by NCDs/LCDs/Articles and MAC jurisdictions (see appended contractor list)
    Glucocorticoid exposure — threshold and duration (GIOP)
    Daily prednisone-equivalent threshold>= 2.5 mg prednisone-equivalent per day
    Minimum expected durationExpected to remain on systemic glucocorticoid therapy for at least 3 months
    High-dose adjustment noteIf glucocorticoid dose >7.5 mg/day, apply FRAX multipliers (major osteoporotic fracture x1.15; hip fracture x1.2) when assessing risk
    Corrected serum calcium — hypercalcemia of malignancy thresholds and targets

    Prior Authorization, Documentation, and Operational Requirements

    Prior Authorization

    Initial prior authorization period and site-of-care requirements

    Prior authorization is issued for an initial 12-month period (365 days) and may be renewed every 12 months. Site-of-care specialty infusion program requirements apply for groups in scope.

    • Initial PA validity: 12 months (365 days).
    • Renewals: may be renewed every 12 months (365 days).
    • Site-of-care: SOC specialty infusion program requirements apply where indicated.
    Prior Authorization

    Prior authorization required when universal criteria are met

    Prior authorization is required and will only be valid when the universal criteria are met, including documented calcium and vitamin D supplementation, absence of hypocalcemia, pregnancy ruled out in biologic females of child-bearing potential, and exclusion of prohibited concomitant denosumab or related therapies.

    • PA applies only when universal criteria are satisfied (calcium/Vit D supplementation, no hypocalcemia).

    Background and Scope

    Denosumab is a subcutaneous monoclonal antibody indicated at lower dose regimens for osteoporosis (branded as Prolia and multiple biosimilars) and at higher dose regimens for oncology indications such as prevention of skeletal‑related events, giant cell tumor of bone, and treatment of hypercalcemia of malignancy (branded as Xgeva and equivalents). Treatment requires calcium and vitamin D supplementation and monitoring for hypocalcemia, and billing must use the specific HCPCS/Q/J codes or NDCs listed in the appendices rather than discontinued or unclassified codes.

    Definitions and Product Groupings

    Universal criteria — examples and key rules
    Calcium and vitamin D supplementationMember must be supplementing with 1,000 mg calcium and at least 400 IU vitamin D daily
    No hypocalcemiaMember must not have hypocalcemia prior to administration
    Pregnancy checkPregnancy must be ruled out in biologic females of child-bearing potential before administration
    Prohibited combinationsDenosumab must not be used in combination with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/related peptides
    Contraindications to injectable bisphosphonate therapy — examples
    Pre-existing hypocalcemiaDocumented pre-existing hypocalcemia is a contraindication to injectable bisphosphonate therapy
    Policy Summary
    PayerModa Health
    PolicyDenosumab (M-0098) — coverage criteria for Prolia, Xgeva, and biosimilars
    Policy CodePolicy M-0098
    Change TypeNo material changes
    Effective DateMay 5, 2026
    Last ReviewMay 5, 2026
    Next Review DateMay 5, 2026
    Key ActionObtain prior authorization (initial PA valid 12 months; renew every 12 months) and document calcium/vitamin D supplementation plus indication-supporting diagnostics or prior bisphosphonate trial when required.
    SourceLink
    On This Page
    Coverage Criteria for Denosumab ProductsBilling, HCPCS, NDCs and Diagnosis CodesPrior Authorization, Documentation, and Operational RequirementsBackground and ScopeDefinitions and Product Groupings
    Hypercalcemia of Malignancy: Member ≥ 18 years AND diagnosis of cancer AND (refractory hypercalcemia defined as albumin-corrected calcium >12.5 mg/dL despite ≥7 day trial of IV bisphosphonates) OR documented contraindication/intolerance to IV bisphosphonatesalbumin-corrected calcium >12.5 mg/dL

    Response target for therapy: corrected serum calcium ≤ 11.5 mg/dL

    Systemic Mastocytosis: Member has osteopenia or osteoporosis with coexisting bone pain AND denosumab used as second-line if not responding to bisphosphonates OR member not candidate for bisphosphonates due to renal insufficiency

    Compendia-recommended indication(s)

    Refractory hypercalcemia thresholdAlbumin-corrected calcium > 12.5 mg/dL despite >=7 day trial of IV bisphosphonates
    Treatment response targetCorrected serum calcium <= 11.5 mg/dL as the response goal
    Alternate pathwayIf documented contraindication or intolerance to IV bisphosphonates, denosumab may be considered for hypercalcemia of malignancy
    Billing unit definition — HCPCS unit to mg mapping
    Billing unit definition1 billable HCPCS unit = 1 mg of denosumab
    Example (Prolia/Xgeva HCPCS)J0897 and multiple Q-codes are defined as 1 mg per billable unit in the policy code listings
    Implication for dosing limitsUse unit-to-mg conversion to apply product-specific max units (e.g., 60 units = 60 mg) when enforcing limits
    Diagnosis presence — ICD-10 code requirement to support coverage
    Diagnosis requirementPresence of one of the listed ICD-10 codes from Appendix 1 on the claim or medical record is required to support coverage
    Acceptable code examples (Prolia group)M80.*, M81.*, M85.* and related osteoporosis and history codes listed in Appendix 1
    Documentation instructionInclude the applicable ICD-10 code on the claim and in supporting medical records per product grouping
  1. Pregnancy must be ruled out in biologic females of child-bearing potential prior to administration.
  2. Denosumab must not be used in combination with other denosumab products, bisphosphonates, romosozumab, or parathyroid hormone analogs/related peptides.
  3. Prior Authorization

    PA applies to denosumab products; biosimilar and J‑code considerations

    Prior authorization is applied to denosumab products per the plan’s utilization management approach; specific HCPCS/Q-codes and J3590 entries are listed for biosimilars and unclassified biologics and are considered in PA decisions.

    • PA considerations include listed biosimilar Q‑codes (e.g., Q5159, Q5161, Q5162, Q5167) and J3590 (unclassified biologics).
    • Utilization management (NQTL) factors inform when PA is required or how it is applied.
    Note

    Verify Medicare NCD/LCD/Article applicability for outpatient denosumab

    When billing Medicare Part B patients, providers must verify and follow applicable Medicare NCDs, LCDs, and Articles, since outpatient denosumab coverage is governed by CMS guidance where applicable.

    • Medicare Part B outpatient drug coverage is subject to the Medicare Benefit Policy Manual and applicable NCDs/LCDs/Articles.
    • Providers should consult CMS coverage database and local contractor policies for applicable rules.
    Step Therapy

    Step therapy: minimum 12‑month bisphosphonate trial required (unless contraindicated)

    For osteoporosis and glucocorticoid‑induced osteoporosis indications, members must have documented treatment failure after at least a 12‑month trial of bisphosphonates, unless there is a documented contraindication or intolerance to both oral and IV bisphosphonates.

    • Minimum bisphosphonate trial: 12 months (oral or IV) with documented treatment failure or ineffective response.
    • Alternatively, documented contraindication or intolerance to BOTH oral and IV bisphosphonates satisfies the prerequisite.
    Prior Authorization

    Prerequisite therapy: try bisphosphonates or document contraindication/intolerance

    Certain indications require prior use of and inadequate response to bisphosphonates (or documented contraindication/intolerance). Examples include a ≥3‑month trial of zoledronic acid for prevention of skeletal‑related events and prior bisphosphonate therapy for osteoporosis or GIOP.

    • Prevention of skeletal‑related events: trial of zoledronic acid ≥3 months with inadequate response, contraindication, or intolerance.
    • Osteoporosis/GIOP: documented failure or intolerance to oral and IV bisphosphonates as specified in indication criteria.
    Note

    Step therapy algorithm not specified in this section

    The policy segment does not provide a detailed stepwise algorithm beyond the listed prerequisite and exception statements; no explicit multi‑step flow is specified here.

    • No explicit step therapy algorithm is present in this document segment; prerequisites and exceptions are described, but a full stepwise sequence is not included.
    Documentation Required

    Document calcium/Vitamin D supplementation and evidence of osteoporosis

    Document that the member is supplementing with 1,000 mg calcium and at least 400 IU vitamin D daily and include evidence of osteoporosis or other covered indication (e.g., DXA T‑score, history of fragility fracture, or FRAX score) when requesting authorization.

    • Calcium supplementation: 1,000 mg daily.
    • Vitamin D supplementation: at least 400 IU daily.
    • Evidence of osteoporosis: T‑score ≤ −2.5, fragility hip/spine fracture history, or qualifying FRAX thresholds as listed.
    Documentation Required

    Renewal: document continued benefit and absence of unacceptable toxicity

    For renewal requests, provide documentation that the member continues to meet universal and indication‑specific criteria, has not experienced unacceptable toxicity, and demonstrates continued benefit (e.g., absence of new fractures, improved BMD, disease stabilization, or corrected serum calcium targets for hypercalcemia).

    • Renewal requires continued fulfillment of universal and indication‑specific criteria (excluding prior prerequisite therapy).
    • Document absence of unacceptable toxicity (examples provided) and evidence of therapeutic benefit per indication.
    Billing Rule

    Include correct product NDC and HCPCS/Q/J code when billing

    Include the appropriate product identifiers when billing: the product NDC(s) and the correct HCPCS/Q‑code or J‑code for the denosumab formulation administered per the policy appendices.

    • List the applicable NDC from Appendix 1 for the product administered (Prolia/Xgeva and biosimilars listed).
    • Use the correct HCPCS (e.g., J0897) or biosimilar Q‑code when submitting claims.
    Documentation Required

    Use listed ICD‑10 diagnosis codes to support coverage

    Ensure an appropriate ICD‑10 diagnosis code from the policy appendices is present on the claim or in the medical record to support medical necessity (examples include M80.*, M81.*, M85.*, malignancy code ranges, and history codes listed in Appendix 1).

    • Use one of the listed ICD‑10 codes or code ranges from Appendix 1 that correspond to the denosumab product grouping.
    • Presence of a covered diagnosis code on the claim or documentation supports coverage.
    Denial Risk

    Denial risk: hypocalcemia, lack of supplementation, or pregnancy not ruled out

    There is a risk of denial if the member has hypocalcemia, is not supplementing with calcium and vitamin D as required, or if pregnancy in biologic females of child‑bearing potential has not been ruled out prior to administration.

    • Administration is not appropriate when the member has hypocalcemia.
    • Denial risk if required calcium (1,000 mg) and vitamin D (≥400 IU) supplementation are not documented.
    • Pregnancy must be ruled out in biologic females of child‑bearing potential to avoid denial risk.
    Prior Authorization

    PA application informed by NQTL assessment

    Prior authorization is applied based on the plan’s NQTL assessment; factors considered include indication, safety/efficacy, and drug cost, which inform utilization management and PA decisions.

    • Appendix A NQTL checklist documents the factors considered when designing and applying PA.
    • Factors include indication relevance, safety/efficacy, and cost.
    Billing Rule

    Claims may be subject to Medicare NCDs/LCDs/Articles — verify contractor rules

    Claims for outpatient denosumab drugs may be subject to Medicare NCDs, LCDs, or Articles; providers billing Medicare should consult applicable contractor policies and the CMS coverage database to ensure compliance.

    • Medicare Part B outpatient drug coverage follows the Medicare Benefit Policy Manual and applicable NCDs/LCDs/Articles.
    • Providers should search the CMS coverage database for relevant NCD/LCD/Article guidance for the MAC jurisdiction.
    Note

    Reserved

    Reserved.

    Renal insufficiency thresholdDocumented pre-existing renal insufficiency defined as creatinine clearance < 30–35 mL/min is an example contraindication to bisphosphonates
    Clinical implicationIf contraindications to bisphosphonates exist, denosumab may be considered per indication-specific rules
    Denosumab products and biosimilars — branded and commercial names listed
    Branded denosumab productsProlia and Xgeva are listed as branded denosumab products in the policy references
    Multiple biosimilars listedNumerous denosumab biosimilars (e.g., Jubbonti, Ospomyv/Denosumab-dssb, Stoboclo/Denosumab-bmwo, Bomyntra/Denosumab-bnht, Aukelso, Bosaya, Bildyos, Bilprevda, Enoby, Xbryk, Xtrenbo, Jubereq, Oziltus, Boncresa) are enumerated with package insert references and NDCs
    Coding associationEach branded and biosimilar product is associated with specific HCPCS/Q-codes and NDC listings in the appendices
    Product grouping — covered diagnosis code groupings by denosumab product
    Prolia product grouping (osteoporosis)Appendix 1 groups Prolia and multiple biosimilars with osteoporosis-related ICD-10 codes (e.g., M80.*, M81.*, M85.*) to support Prolia-group coverage
    Xgeva product grouping (oncology)Appendix 1 groups Xgeva and multiple biosimilars with malignancy and bone tumor ICD-10 code ranges (e.g., C00–C80, C40–C41, E83.52) to support Xgeva-group coverage
    Use for claim supportSelect the diagnosis code from the product-specific grouping in Appendix 1 corresponding to the administered denosumab product for coverage documentation